• [Hankyung BIO Insight] EOFlow Plans for Diversification to Non-insulin Drug Delivery

    Apr.26.2021
  • EOFlow's product diversification plan was introduced on Hankyung BIO Insight on 04/25/2021 (in Korean only): 
    https://www.hankyung.com/society/article/2021042537721

    In summary, reporter Sun-a Lee from Bio & Healthcare department in the Korea Economic Daily announced that EOFlow plans to leverage advantages of its recently launched wearable insulin pump EOPatch and expand the business to other non-insulin drug delivery. The advantages of its core platform technology include small, light, low-power, high-output and low-cost EOPump, which makes the diversification to non-insulin drug delivery possible. 
    The reporter mentioned that there is a wide range of subcutaneous drug candidates for EOFlow, including hormonal drug, pain management and chemical drugs. Jesse Kim, the founding CEO of EOFlow mentioned that the company is developing non-insulin wearable drug pumps and it is under discussion with several domestic and international pharmaceutical companies and plans to have partnership or JV arranged.

We use cookies. By continuing to use our site you accept our cookie policy. Find out more about our privacy policy here

PRIVACY POLICY